Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-influenza siRNA-MNM
- Development stage
- Preclinical
- Lead developer
- Interna Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intranasal
01
Overview
Anti-influenza siRNA-MNM is a preclinical-stage therapeutic candidate developed by Interna Therapeutics for the treatment of influenza. The drug utilizes small interfering RNA (siRNA) to target and silence a highly conserved sequence within the influenza virus genome, thereby inhibiting viral replication. It is delivered using Interna's proprietary MNM (Molecular Nano-Mesh) delivery platform, which is designed for efficient intracellular delivery of oligonucleotides. The drug is administered via the intranasal route to target the primary site of infection in the respiratory tract.
- Other names
- anti-influenza siRNA-MNM
02
Targets
Influenza A virus segment 7 mRNA
Beyond the preview
Go deeper on anti-influenza siRNA-MNM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-influenza siRNA-MNM.